Close

Industry Reports

Stada Arzneimittel AG announces First quarter of 2016 and result shows key earnings figures substantially higher than previous year

Group sales rise by 2 percent – adjusted by +4 percent Adjusted EBITDA declines slightly by 1 percent Adjusted net income increases by 6 percent Sales increase in Branded Products by +3 percent – adjusted +4 percent Very...

Lundbeck announces the 2016 guidance raised based on solid sales performance and improve profitability

Revenue reached DKK 3,770 million in the first quarter of 2016 representing an increase of 6% both reported and in local currencies compared to the same period last year   Total revenue have delivered a...

Bayer, BioNTech collaborate to develop mRNA vaccines & therapeutics for animal health applications

Bayer and BioNTech AG, a leading immunotherapy company headquartered in Mainz, Germany have entered into an agreement to develop novel, first-in-class mRNA vaccines and therapeutics specifically for Animal Health applications. BioNTech will contribute its proprietary mRNA...

DePuy Synthes Companies of Johnson & Johnson acquired Biomedical Enterprises, inc

Acquisition of Nitinol Implant Company Strengthens Johnson & Johnson Medical Devices Position in Elective Extremity Surgery, the Fastest Growing Segment in Orthopaedics. DePuy Orthopaedics, Inc part of the DePuy Synthes Companies of Johnson & Johnson, announced...

AstraZeneca acquired Takedas respiratory business

AstraZeneca announced that it has completed the acquisition of the core respiratory business of Takeda Pharmaceutical Company Limited . The agreement, announced in December 2015, includes the expansion of rights to roflumilast (marketed as Daliresp in the US and...

The 2016 first quarter operating profit of Novo Nordisk increased by 10% in local currencies

Sales increased by 9% in local currencies and by 8% in Danish kroner to DKK 27.2 billion. Sales of Victoza® increased by 15% (16% in Danish kroner). Sales of Levemir® increased by 9% (8% in Danish kroner)....

Abbott to acquire st. Jude medical

Combination will create a premier medical device leader and strengthen abbott's long-term growth potential Acquisition will enhance abbott's global scale and capabilities and will further diversify its portfolio of best-in-class products and revenue sources Combined portfolio will include...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read